L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution

Cell Rep. 2018 Jun 26;23(13):3730-3740. doi: 10.1016/j.celrep.2018.05.090.

Abstract

LINE-1 (L1) retrotransposons are a source of insertional mutagenesis in tumor cells. However, the clinical significance of L1 mobilization during tumorigenesis remains unclear. Here, we applied retrotransposon capture sequencing (RC-seq) to multiple single-cell clones isolated from five ovarian cancer cell lines and HeLa cells and detected endogenous L1 retrotransposition in vitro. We then applied RC-seq to ovarian tumor and matched blood samples from 19 patients and identified 88 tumor-specific L1 insertions. In one tumor, an intronic de novo L1 insertion supplied a novel cis-enhancer to the putative chemoresistance gene STC1. Notably, the tumor subclone carrying the STC1 L1 mutation increased in prevalence after chemotherapy, further increasing STC1 expression. We also identified hypomethylated donor L1s responsible for new L1 insertions in tumors and cultivated cancer cells. These congruent in vitro and in vivo results highlight L1 insertional mutagenesis as a common component of ovarian tumorigenesis and cancer genome heterogeneity.

Keywords: L1; LINE-1; chemoresistance; ovarian cancer; retrotransposon.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Cell Line, Tumor
  • DNA Methylation
  • Drug Resistance, Neoplasm
  • Evolution, Molecular*
  • Female
  • Gene Expression Regulation, Neoplastic
  • Glycoproteins / genetics
  • Glycoproteins / metabolism
  • Humans
  • Long Interspersed Nucleotide Elements / genetics*
  • Loss of Heterozygosity / genetics
  • Mutagenesis, Insertional
  • Mutation
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / pathology*

Substances

  • Antineoplastic Agents
  • Glycoproteins
  • teleocalcin